Formulation meets function: addressing palatability in drug development (part I)

Published: 1-Sep-2025
Research & Development

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth

You need to be a subscriber to read this article.
Click here to find out more.

However, drug developers face numerous challenges when creating truly patient-friendly dosage forms and must work within the strict constraints imposed by formulation requirements to avoid compromising therapeutic efficacy. 

Sophie Wallet Crouzet, Global Flavourist, and Lyzandra Passarella-Dutour, Global Taste Technical Director, Health, Nutrition and Care, at dsm­-firmenich, report.

This article explores some of these common challenges and examines how working with a panel of experts — from flavourists, scientists and regulatory specialists to consumer insight professionals — can help to overcome these barriers, leading to the development of medications that enhance patient compliance. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
See more

You may also like

Ingredients

dsm-firmenich's CBtru demonstrates similar bioavailability to commercially available Epidiolex

Read more
The cannabidiol (CBD)-based drug product intermediate is absorbed into the bloodstream at a similar level compared with the only commercially approved CBD drug, Epidiolex

Trending Articles

  1. Indena and TCG GreenChem join forces to advance next-generation ADC technologies Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)
  2. Meet Navetta: new approach to safety testing of drugs and particles Turn inhalation research upside down
  3. Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
  4. Lilly's Verzenio (abemaciclib) increases overall survival in HR+/HER2- high-risk early breast cancer with 2 years of therapy Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with endocrine therapy alone
  5. Bowel cancer test could be used to detect other serious diseases, study finds A new study, led by experts at the University of Nottingham, has found that people who test positive following a stool test for symptoms of bowel cancer had double the risk of death after one year than people who had negative tests ... and most of the deaths were because of other causes

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Ingredients

dsm-firmenich's CBtru demonstrates similar bioavailability to commercially available Epidiolex

The cannabidiol (CBD)-based drug product intermediate is absorbed into the bloodstream at a similar level compared with the only commercially approved CBD drug, Epidiolex
Ingredients

The roadmap to success in the cannabinoid drug development journey

The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile
Ingredients

CBD: the new frontier in medical science

Early stage drug development plays an important role in expanding treatment options that will support the health of patients globally. To create bespoke drug products, it is important to explore and understand the benefits of new actives emerging on the market, such as cannabidiol (CBD), explains Kelsey Achenbach, Senior Director, Pharma and Medical Nutrition at DSM
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Can new discoveries prevent an antibiotic Armageddon?

Governments are waking up to the catastrophe of drug resistance and healthcare without antibiotics. But is extra funding the answer or could the pharma industry be doing more?
Ingredients

Firmenich opens R&D centre for fragrances, flavours and ingredients in Shanghai

Aims to accelerate and expand development pipeline in China and Asia Pacific
Manufacturing

DSM launches InnoSyn route scouting services

To meet r&d outsourcing needs
Manufacturing

Chemspec News: DSM and Novacta enter C. difficile project

DSM BioSolutions has entered into an agreement with Novacta Biosystems in Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule
Subscribe now